

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waiver under 18 U.S.C. § 208(b)(3) and 21 U.S.C. §355 (n)(4)

Pamela J. Haylock, R.N., M.A., Ph.D. (c)

Committee: Oncologic Drugs Advisory Committee

Meeting Date: March 14, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to clinical studies of daunomycin to be conducted under the Best Pharmaceuticals for Children Act (BPCA), I am eligible to receive waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4).

Type of Interest	Nature	Magnitude
Stock	Competitor	Valued at less than \$5,001
Stock	Competitor	Valued from \$25,001 to \$50,000

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued. The public disclosure will be accomplished by reading the statement into the record and by making a written copy publicly available at the time of the meeting. I understand that without public disclosure of these interests, the waivers are not valid.

Signature of SGE

Date